Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.

Abstract

OBJECTIVE To evaluate the validity of enthesitis indices in patients with peripheral spondyloarthritis (pSpA). METHODS The ABILITY-2 study evaluated the efficacy of adalimumab (ADA) versus placebo (PBO) in patients with active pSpA over 12 weeks. Patients received open-label ADA for an additional 144 weeks. Twenty-nine enthesitis sites used in 3… (More)
DOI: 10.3899/jrheum.160387

Topics

7 Figures and Tables